TY  - JOUR
AU  - Petković, Aleksa
AU  - Erceg, Sanja
AU  - Munjas, Jelena
AU  - Ninić, Ana
AU  - Vladimirov, Sandra
AU  - Davidović, Aleksandar
AU  - Vukmirović, Luka
AU  - Milanov, Marko
AU  - Cvijanović, Dane
AU  - Mitić, Tijana
AU  - Sopić, Miron
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4955
AB  - Current clinical data show that, despite constant efforts to develop novel therapies and clinical approaches, atherosclerotic cardiovascular diseases (ASCVD) are still one of the leading causes of death worldwide. Advanced and unstable atherosclerotic plaques most often trigger acute coronary events that can lead to fatal outcomes. However, despite the fact that different plaque phenotypes may require different treatments, current approaches to prognosis, diagnosis, and classification of acute coronary syndrome do not consider the diversity of plaque phenotypes. Long non-coding RNAs (lncRNAs) represent an important class of molecules that are implicated in epigenetic control of numerous cellular processes. Here we review the latest knowledge about lncRNAs’ influence on plaque development and stability through regulation of immune response, lipid metabolism, extracellular matrix remodelling, endothelial cell function, and vascular smooth muscle function, with special emphasis on pro-atherogenic and anti-atherogenic lncRNA functions. In addition, we present current challenges in the research of lncRNAs’ role in atherosclerosis and translation of the findings from animal models to humans. Finally, we present the directions for future lncRNA-oriented research, which may ultimately result in patient-oriented therapeutic strategies for ASCVD.
PB  - MDPI
T2  - Cells
T1  - LncRNAs as Regulators of Atherosclerotic Plaque Stability
VL  - 12
IS  - 14
DO  - 10.3390/cells12141832
ER  - 

@article{
author = "Petković, Aleksa and Erceg, Sanja and Munjas, Jelena and Ninić, Ana and Vladimirov, Sandra and Davidović, Aleksandar and Vukmirović, Luka and Milanov, Marko and Cvijanović, Dane and Mitić, Tijana and Sopić, Miron",
year = "2023",
abstract = "Current clinical data show that, despite constant efforts to develop novel therapies and clinical approaches, atherosclerotic cardiovascular diseases (ASCVD) are still one of the leading causes of death worldwide. Advanced and unstable atherosclerotic plaques most often trigger acute coronary events that can lead to fatal outcomes. However, despite the fact that different plaque phenotypes may require different treatments, current approaches to prognosis, diagnosis, and classification of acute coronary syndrome do not consider the diversity of plaque phenotypes. Long non-coding RNAs (lncRNAs) represent an important class of molecules that are implicated in epigenetic control of numerous cellular processes. Here we review the latest knowledge about lncRNAs’ influence on plaque development and stability through regulation of immune response, lipid metabolism, extracellular matrix remodelling, endothelial cell function, and vascular smooth muscle function, with special emphasis on pro-atherogenic and anti-atherogenic lncRNA functions. In addition, we present current challenges in the research of lncRNAs’ role in atherosclerosis and translation of the findings from animal models to humans. Finally, we present the directions for future lncRNA-oriented research, which may ultimately result in patient-oriented therapeutic strategies for ASCVD.",
publisher = "MDPI",
journal = "Cells",
title = "LncRNAs as Regulators of Atherosclerotic Plaque Stability",
volume = "12",
number = "14",
doi = "10.3390/cells12141832"
}

Petković, A., Erceg, S., Munjas, J., Ninić, A., Vladimirov, S., Davidović, A., Vukmirović, L., Milanov, M., Cvijanović, D., Mitić, T.,& Sopić, M.. (2023). LncRNAs as Regulators of Atherosclerotic Plaque Stability. in Cells
MDPI., 12(14).
https://doi.org/10.3390/cells12141832

Petković A, Erceg S, Munjas J, Ninić A, Vladimirov S, Davidović A, Vukmirović L, Milanov M, Cvijanović D, Mitić T, Sopić M. LncRNAs as Regulators of Atherosclerotic Plaque Stability. in Cells. 2023;12(14).
doi:10.3390/cells12141832 .

Petković, Aleksa, Erceg, Sanja, Munjas, Jelena, Ninić, Ana, Vladimirov, Sandra, Davidović, Aleksandar, Vukmirović, Luka, Milanov, Marko, Cvijanović, Dane, Mitić, Tijana, Sopić, Miron, "LncRNAs as Regulators of Atherosclerotic Plaque Stability" in Cells, 12, no. 14 (2023),
https://doi.org/10.3390/cells12141832 . .

TY  - JOUR
AU  - Lalosević, Miodrag
AU  - Kotur-Stevuljević, Jelena
AU  - Vekić, Jelena
AU  - Rizzo, Manfredi
AU  - Kosanović, Tijana
AU  - Blagojević-Perović, Ivana
AU  - Zeljković, Aleksandra
AU  - Jeremić, Danilo
AU  - Mihajlović, Marija
AU  - Petković, Aleksa
AU  - Hajdarpasić, Lejla
AU  - Đorđević, Marjana
AU  - Dobrilović, Violeta
AU  - Erceg, Sanja
AU  - Vujčić, Sanja
AU  - Marjanović, Jelena
AU  - Jovanović-Milijić, Jovana
AU  - Saponjski, Jovica
AU  - Bogavac-Stanojević, Nataša
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4335
AB  - Background. Metabolic alterations, particularly disorders of lipoprotein metabolism in COVID-19, may affect the course and outcome of the disease. This study aims at evaluating the lipoprotein profile and redox status in SARS-CoV-2 infected patients with different pneumonia severity and their association with lethal outcomes. Methods. The prospective cohort study was performed on 98 COVID-19 patients with mild, moderate, and severe pneumonia. Lipid and inflammatory parameters, lipoprotein subclasses, and redox status biomarkers were determined at the study entry and after one week. Results. Compared to patients with mild and moderate pneumonia, severely ill patients had higher oxidised low-density lipoprotein (oxLDL) and malondialdehyde levels and lower high-density lipoprotein cholesterol (HDL-C) concentrations and paraoxonase 1 activity. Reduction in the proportion of large HDL 2a subclasses with a concomitant increase in the proportion of smallest HDL 3c and small dense LDL (sdLDL) particles was observed in patients with severe disease during the time. However, these changes were reversed in the mild and moderate groups. The results showed a positive association between changes in oxLDL and total antioxidative status. However, prooxidants and antioxidants in plasma were lower in patients with lethal outcomes. Conclusions. Increased levels of oxLDL and sdLDL particles may contribute to the severity of COVID-19. The role of oxidative stress should be clarified in further studies, mainly its association with lethal outcomes.
PB  - Hindawi Limited
T2  - Oxidative Medicine and Cellular Longevity
T1  - Alteration in Redox Status and Lipoprotein Profile in COVID-19 Patients with Mild, Moderate, and Severe Pneumonia
VL  - 2022
DO  - 10.1155/2022/8067857
ER  - 

@article{
author = "Lalosević, Miodrag and Kotur-Stevuljević, Jelena and Vekić, Jelena and Rizzo, Manfredi and Kosanović, Tijana and Blagojević-Perović, Ivana and Zeljković, Aleksandra and Jeremić, Danilo and Mihajlović, Marija and Petković, Aleksa and Hajdarpasić, Lejla and Đorđević, Marjana and Dobrilović, Violeta and Erceg, Sanja and Vujčić, Sanja and Marjanović, Jelena and Jovanović-Milijić, Jovana and Saponjski, Jovica and Bogavac-Stanojević, Nataša",
year = "2022",
abstract = "Background. Metabolic alterations, particularly disorders of lipoprotein metabolism in COVID-19, may affect the course and outcome of the disease. This study aims at evaluating the lipoprotein profile and redox status in SARS-CoV-2 infected patients with different pneumonia severity and their association with lethal outcomes. Methods. The prospective cohort study was performed on 98 COVID-19 patients with mild, moderate, and severe pneumonia. Lipid and inflammatory parameters, lipoprotein subclasses, and redox status biomarkers were determined at the study entry and after one week. Results. Compared to patients with mild and moderate pneumonia, severely ill patients had higher oxidised low-density lipoprotein (oxLDL) and malondialdehyde levels and lower high-density lipoprotein cholesterol (HDL-C) concentrations and paraoxonase 1 activity. Reduction in the proportion of large HDL 2a subclasses with a concomitant increase in the proportion of smallest HDL 3c and small dense LDL (sdLDL) particles was observed in patients with severe disease during the time. However, these changes were reversed in the mild and moderate groups. The results showed a positive association between changes in oxLDL and total antioxidative status. However, prooxidants and antioxidants in plasma were lower in patients with lethal outcomes. Conclusions. Increased levels of oxLDL and sdLDL particles may contribute to the severity of COVID-19. The role of oxidative stress should be clarified in further studies, mainly its association with lethal outcomes.",
publisher = "Hindawi Limited",
journal = "Oxidative Medicine and Cellular Longevity",
title = "Alteration in Redox Status and Lipoprotein Profile in COVID-19 Patients with Mild, Moderate, and Severe Pneumonia",
volume = "2022",
doi = "10.1155/2022/8067857"
}

Lalosević, M., Kotur-Stevuljević, J., Vekić, J., Rizzo, M., Kosanović, T., Blagojević-Perović, I., Zeljković, A., Jeremić, D., Mihajlović, M., Petković, A., Hajdarpasić, L., Đorđević, M., Dobrilović, V., Erceg, S., Vujčić, S., Marjanović, J., Jovanović-Milijić, J., Saponjski, J.,& Bogavac-Stanojević, N.. (2022). Alteration in Redox Status and Lipoprotein Profile in COVID-19 Patients with Mild, Moderate, and Severe Pneumonia. in Oxidative Medicine and Cellular Longevity
Hindawi Limited., 2022.
https://doi.org/10.1155/2022/8067857

Lalosević M, Kotur-Stevuljević J, Vekić J, Rizzo M, Kosanović T, Blagojević-Perović I, Zeljković A, Jeremić D, Mihajlović M, Petković A, Hajdarpasić L, Đorđević M, Dobrilović V, Erceg S, Vujčić S, Marjanović J, Jovanović-Milijić J, Saponjski J, Bogavac-Stanojević N. Alteration in Redox Status and Lipoprotein Profile in COVID-19 Patients with Mild, Moderate, and Severe Pneumonia. in Oxidative Medicine and Cellular Longevity. 2022;2022.
doi:10.1155/2022/8067857 .

Lalosević, Miodrag, Kotur-Stevuljević, Jelena, Vekić, Jelena, Rizzo, Manfredi, Kosanović, Tijana, Blagojević-Perović, Ivana, Zeljković, Aleksandra, Jeremić, Danilo, Mihajlović, Marija, Petković, Aleksa, Hajdarpasić, Lejla, Đorđević, Marjana, Dobrilović, Violeta, Erceg, Sanja, Vujčić, Sanja, Marjanović, Jelena, Jovanović-Milijić, Jovana, Saponjski, Jovica, Bogavac-Stanojević, Nataša, "Alteration in Redox Status and Lipoprotein Profile in COVID-19 Patients with Mild, Moderate, and Severe Pneumonia" in Oxidative Medicine and Cellular Longevity, 2022 (2022),
https://doi.org/10.1155/2022/8067857 . .

TY  - CONF
AU  - Erceg, Sanja
AU  - Tomašević, Ratko
AU  - Ninić, Ana
AU  - Pavlović, Aleksandar
AU  - Guzonjić, Azra
AU  - Vujčić, Sanja
AU  - Mamić, Milica
AU  - Mitrović, Bojan
AU  - Gluvić, Zoran
AU  - Kotur-Stevuljević, Jelena
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4511
AB  - Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease,
present in up to 30% of the adult population worldwide (1). Triglycerides accumulation in
hepatocytes (steatosis) represents the root cause of NAFLD and is associated with oxidative
stress, which could further lead to fibrosis and cell death of hepatocytes (2). The aim of this
research was to identify redox status markers for predicting the risk of developing steatosis.
158 participants were included. Steatosis was confirmed by ultrasound in 101 subjects,
while the remaining 57 were in the control group. The following markers of redox status
were determined in serum and plasma samples of all subjects: superoxide dismutase 1
(SOD1), paraoxonase (PON1), malondialdehyde (MDA) and superoxide anion (O2.-). For this
purpose, spectrophotometric methods and enzyme immunosorbent assays were used. SOD1
was statistically significantly higher (P<0.001), while O2 .- was significantly lower in the
patient group (P<0.001). SOD1 was significantly negatively correlated with O2.- (ρ= -0.494,
P<0.001) and MDA (ρ= -0.242, P=0.002). Univariate binary logistic regression analysis
showed a positive association between SOD1 and the presence of steatosis (OR=1.018, 95%
CI 1.005-1.031; P=0.005), as well as a negative association between O2 .- and the presence of
steatosis (OR=0.959, 95% CI 0.941-0.978; P<0.001). Multivariate analysis singled out SOD1
(OR=1.024, 95% CI 1.006-1.041; P=0.007) and O2.- (OR=0.965, 95% CI 0.942-0.989;
P=0.004) as independent predictors for the presence of steatosis in our subjects. The redox
status parameters, SOD1 and O2, respectively, showed a positive and negative prediction of
the presence of statosis in our subjects.
AB  - Nealkoholna masna bolest jetre (eng. nonalcoholic fatty liver disease, NAFLD) je
najčešće hronično oboljenje jetre, prisutno i u do 30% adultne populacije širom sveta (1).
Značajnu ulogu u nastanku NAFLD ima akumulacija triglicerida u hepatocitima – steatoza,
koja je povezana sa oksidativnim stresom, a koji dalje vodi fibrozi i ćelijskoj smrti hepatocita
(2). Cilj ovog istraživanja bio je identifikacija markera redoks statusa za predviđanje rizika za
nastanak steatoze. Studija je obuhvatila 158 ispitanika iz Kliničko bolničkog centra Zemun.
Steatoza je potvrđena ultrazvukom kod 101 ispitanika, dok je preostalih 57 činilo kontrolnu
grupu. U uzorcima seruma i plazme svih ispitanika određeni su sledeći markeri redoks
statusa: superoksid dismutaza 1 (SOD1), paraoksonaza (PON1), malondialdehid (MDA) i
superoksidni anjon (O2.-). U tu svrhu korišćene su spektrofotometrijske metode i enzimski
imunosorbentni testovi. SOD1 je bila statistički značajno viša (P<0,001), dok O 2.- značajno
niži u grupi pacijenata (P<0,001), dok se PON1 i MDA nisu značajno razlikovali između
grupa. SOD1 je bila u značajnoj negativnoj korelaciji sa O 2.- (ρ=-0,494, P<0,001) i MDA (ρ= -
0,242, P=0,002). Univarijatna binarna logistička regresiona analiza je pokazala pozitivnu
asocijaciju između SOD1 i prisustva steatoze (OR=1,018, 95% CI 1,005-1,031; P=0,005), kao i
negativnu asocijaciju između O 2.- i prisustva steatoze (OR=0,959, 95% CI 0,941-0,978;
P<0,001). Multivarijantna analiza je izdvojila SOD1 (OR=1,024, 95% CI 1,006-1,041;
P=0,007) i O2.- (OR=0,965, 95% CI 0,942-0,989; P=0,004) kao nezavisne prediktore za
prisustvo steatoze kod naših ispitanika. Parametri redoks statusa, SOD1 i O 2.- redom, su
pokazali pozitivnu, odnosno negativnu predikciju prisustva statoze kod naših ispitanika.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Markers of redox status in patients with nonalcoholic fatty liver disease
T1  - Markeri redoks statusa kod pacijenata sa nealkoholnom masnom bolešću jetre
VL  - 72
IS  - 4 suplement
SP  - S233
EP  - S234
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4511
ER  - 

@conference{
author = "Erceg, Sanja and Tomašević, Ratko and Ninić, Ana and Pavlović, Aleksandar and Guzonjić, Azra and Vujčić, Sanja and Mamić, Milica and Mitrović, Bojan and Gluvić, Zoran and Kotur-Stevuljević, Jelena",
year = "2022",
abstract = "Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease,
present in up to 30% of the adult population worldwide (1). Triglycerides accumulation in
hepatocytes (steatosis) represents the root cause of NAFLD and is associated with oxidative
stress, which could further lead to fibrosis and cell death of hepatocytes (2). The aim of this
research was to identify redox status markers for predicting the risk of developing steatosis.
158 participants were included. Steatosis was confirmed by ultrasound in 101 subjects,
while the remaining 57 were in the control group. The following markers of redox status
were determined in serum and plasma samples of all subjects: superoxide dismutase 1
(SOD1), paraoxonase (PON1), malondialdehyde (MDA) and superoxide anion (O2.-). For this
purpose, spectrophotometric methods and enzyme immunosorbent assays were used. SOD1
was statistically significantly higher (P<0.001), while O2 .- was significantly lower in the
patient group (P<0.001). SOD1 was significantly negatively correlated with O2.- (ρ= -0.494,
P<0.001) and MDA (ρ= -0.242, P=0.002). Univariate binary logistic regression analysis
showed a positive association between SOD1 and the presence of steatosis (OR=1.018, 95%
CI 1.005-1.031; P=0.005), as well as a negative association between O2 .- and the presence of
steatosis (OR=0.959, 95% CI 0.941-0.978; P<0.001). Multivariate analysis singled out SOD1
(OR=1.024, 95% CI 1.006-1.041; P=0.007) and O2.- (OR=0.965, 95% CI 0.942-0.989;
P=0.004) as independent predictors for the presence of steatosis in our subjects. The redox
status parameters, SOD1 and O2, respectively, showed a positive and negative prediction of
the presence of statosis in our subjects., Nealkoholna masna bolest jetre (eng. nonalcoholic fatty liver disease, NAFLD) je
najčešće hronično oboljenje jetre, prisutno i u do 30% adultne populacije širom sveta (1).
Značajnu ulogu u nastanku NAFLD ima akumulacija triglicerida u hepatocitima – steatoza,
koja je povezana sa oksidativnim stresom, a koji dalje vodi fibrozi i ćelijskoj smrti hepatocita
(2). Cilj ovog istraživanja bio je identifikacija markera redoks statusa za predviđanje rizika za
nastanak steatoze. Studija je obuhvatila 158 ispitanika iz Kliničko bolničkog centra Zemun.
Steatoza je potvrđena ultrazvukom kod 101 ispitanika, dok je preostalih 57 činilo kontrolnu
grupu. U uzorcima seruma i plazme svih ispitanika određeni su sledeći markeri redoks
statusa: superoksid dismutaza 1 (SOD1), paraoksonaza (PON1), malondialdehid (MDA) i
superoksidni anjon (O2.-). U tu svrhu korišćene su spektrofotometrijske metode i enzimski
imunosorbentni testovi. SOD1 je bila statistički značajno viša (P<0,001), dok O 2.- značajno
niži u grupi pacijenata (P<0,001), dok se PON1 i MDA nisu značajno razlikovali između
grupa. SOD1 je bila u značajnoj negativnoj korelaciji sa O 2.- (ρ=-0,494, P<0,001) i MDA (ρ= -
0,242, P=0,002). Univarijatna binarna logistička regresiona analiza je pokazala pozitivnu
asocijaciju između SOD1 i prisustva steatoze (OR=1,018, 95% CI 1,005-1,031; P=0,005), kao i
negativnu asocijaciju između O 2.- i prisustva steatoze (OR=0,959, 95% CI 0,941-0,978;
P<0,001). Multivarijantna analiza je izdvojila SOD1 (OR=1,024, 95% CI 1,006-1,041;
P=0,007) i O2.- (OR=0,965, 95% CI 0,942-0,989; P=0,004) kao nezavisne prediktore za
prisustvo steatoze kod naših ispitanika. Parametri redoks statusa, SOD1 i O 2.- redom, su
pokazali pozitivnu, odnosno negativnu predikciju prisustva statoze kod naših ispitanika.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Markers of redox status in patients with nonalcoholic fatty liver disease, Markeri redoks statusa kod pacijenata sa nealkoholnom masnom bolešću jetre",
volume = "72",
number = "4 suplement",
pages = "S233-S234",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4511"
}

Erceg, S., Tomašević, R., Ninić, A., Pavlović, A., Guzonjić, A., Vujčić, S., Mamić, M., Mitrović, B., Gluvić, Z.,& Kotur-Stevuljević, J.. (2022). Markers of redox status in patients with nonalcoholic fatty liver disease. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S233-S234.
https://hdl.handle.net/21.15107/rcub_farfar_4511

Erceg S, Tomašević R, Ninić A, Pavlović A, Guzonjić A, Vujčić S, Mamić M, Mitrović B, Gluvić Z, Kotur-Stevuljević J. Markers of redox status in patients with nonalcoholic fatty liver disease. in Arhiv za farmaciju. 2022;72(4 suplement):S233-S234.
https://hdl.handle.net/21.15107/rcub_farfar_4511 .

Erceg, Sanja, Tomašević, Ratko, Ninić, Ana, Pavlović, Aleksandar, Guzonjić, Azra, Vujčić, Sanja, Mamić, Milica, Mitrović, Bojan, Gluvić, Zoran, Kotur-Stevuljević, Jelena, "Markers of redox status in patients with nonalcoholic fatty liver disease" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S233-S234,
https://hdl.handle.net/21.15107/rcub_farfar_4511 .

TY  - CONF
AU  - Vujčić, Sanja
AU  - Kotur-Stevuljević, Jelena
AU  - Beljić Živković, Teodora
AU  - Mišić, Milan
AU  - Mihajlović, Marija
AU  - Erceg, Sanja
AU  - Zeljković, Aleksandra
AU  - Koprivica‐Uzelac, Branka
AU  - Perović‐Blagojević, Iva
AU  - Vekić, Jelena
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4509
AB  - Non-enzymatic glycation, oxidative stress (OS) and dyslipidemia are the main
metabolic alterations behind the development of macrovascular
complications (cardiovascular diseases) of diabetes mellitus (DM).
However, clinical relevance of biomarkers of these processes in patients with microvascular
complications (nephropathy, neuropathy, retinopathy) is less understood. Therefore, the aim
of this study was to examine advanced glycation products (AGEs), biomarkers of OS, and
dyslipidemia in 100 DM patients (33 without microvascular complications and 77 with
complications) and 30 subjects without DM. AGEs levels were higher in patients with
complications than in those without complications (median: 5.72; interquartile range: 4.60-
6.54 U/mL vs. median: 4.84; interquartile range: 4.10-5.40 U/L; P<0.05). In addition to
AGEs, the group with diabetic retinopathy had higher plasma total antioxidant capacity
(P<0.05), while the group with diabetic nephropathy had smaller LDL size than the patients
without these complications (25.48±1.26 nm vs. 26.21±1.19 nm; P<0.05). The patients
with co-existing cardiovascular disease were further characterized by dysfunctional HDL
particles, as evidenced by increased small HDL particles (P<0.05) and reduced paraoxonase-
1 activities. Significant increase in both pro-oxidant-antioxidant balance and ischemia-
modified albumin (P<0.05), with simultaneously decreased activity of superoxide-dismutase
(P<0.05) was found in patients with progressive diabetic neuropathy, indicating the highest
degree of oxidative damage. It can be concluded that patients with microvascular
complications of DM have aggravated redox imbalance and lipid profile alterations. In
addition to metabolic control, strategies aimed at lowering OS and correcting dyslipidemia
can contribute to the prevention of microvascular complications of diabetes.
AB  - Neenzimska glikacija, oksidativni stres (OS) i dislipidemija su glavni metabolički
procesi koji dovode do razvoja makrovaskularnih komplikacija (kardiovaskularnih bolesti)
dijabetesa melitusa (DM). Međutim, klinički značaj određivanja biomarkera ovih procesa
kod pacijenata sa mikrovaskularnim komplikacijama (retinopatija, nefropatija, neuropatija)
nije dovoljno razjašnjen. Cilj ovog istraživanja je bio ispitivanje produkata uznapredovale
glikacije (AGE), biomarkera OS i dislipidemije kod 100 pacijenata sa DM (33 bez
mikrovaskularnih komplikacija i 77 sa komplikacijama) i 30 ispitanika bez DM. Nivo
cirkulišućih AGE je bio značajno viši u grupi pacijenata sa komplikacijama (medijana: 5,72;
interkvartilni raspon: 4,60-6,54 U/mL) u odnosu na pacijente bez komplikacija (medijana:
4,84; interkvartilni raspon 4,10-5,40 U/L; P<0,05). Pored povišenih koncentracija AGE,
pacijenti sa dijabetesnom retinopatijom su imali i povišene vrednosti totalnog oksidativnog
statusa (P<0,05), a pacijenti sa dijabetesnom nefropatijom manje dijametre LDL čestica
(25,48±1,26 nm) u poređenju sa sa pacijentima bez komplikacija (26,21±1,19 nm;
P<0,05). Nadalje, kod pacijenata sa pridruženim makrovaskularnim komplikacijama
(kardiovaskularnim bolestima) utvrđeno je prisustvo disfunkcionalnih HDL čestica, na
osnovu povećanog udela malih HDL čestica (P<0.05) i smanjene aktivnosti paroksonaze-
1. Pacijenti sa progresivnom dijabetesnom neuropatijom su imali značajno povišene
vrednosti prooksidativno-antioksidativnog balansa i ishemijom modifikovanog albumina
(P<0,05), uz istovremeno sniženje aktivnosti superoksid-dismutaze (P<0,05), što ukazuje da
je stepen oksidativnog oštećenja u ovoj grupi bio najveći. Može se zaključiti da, pored
adekvatne metaboliče kontrole, strategije usmerene ka sniženju OS i korekciji dislipidemije,
mogu doprineti prevenciji razvoja mikrovaskularnih komplikacija dijabetesa.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - The importance of advanced glycation end products, lipid and redox biomarkers determination in patients with diabetes mellitus
T1  - Značaj određivanja produkata uznapredovale glikacije i biomarkera lipidnog i redoks statusa kod pacijenata sa dijabetes melitusom
VL  - 72
IS  - 4 suplement
SP  - S229
EP  - S230
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4509
ER  - 

@conference{
author = "Vujčić, Sanja and Kotur-Stevuljević, Jelena and Beljić Živković, Teodora and Mišić, Milan and Mihajlović, Marija and Erceg, Sanja and Zeljković, Aleksandra and Koprivica‐Uzelac, Branka and Perović‐Blagojević, Iva and Vekić, Jelena",
year = "2022",
abstract = "Non-enzymatic glycation, oxidative stress (OS) and dyslipidemia are the main
metabolic alterations behind the development of macrovascular
complications (cardiovascular diseases) of diabetes mellitus (DM).
However, clinical relevance of biomarkers of these processes in patients with microvascular
complications (nephropathy, neuropathy, retinopathy) is less understood. Therefore, the aim
of this study was to examine advanced glycation products (AGEs), biomarkers of OS, and
dyslipidemia in 100 DM patients (33 without microvascular complications and 77 with
complications) and 30 subjects without DM. AGEs levels were higher in patients with
complications than in those without complications (median: 5.72; interquartile range: 4.60-
6.54 U/mL vs. median: 4.84; interquartile range: 4.10-5.40 U/L; P<0.05). In addition to
AGEs, the group with diabetic retinopathy had higher plasma total antioxidant capacity
(P<0.05), while the group with diabetic nephropathy had smaller LDL size than the patients
without these complications (25.48±1.26 nm vs. 26.21±1.19 nm; P<0.05). The patients
with co-existing cardiovascular disease were further characterized by dysfunctional HDL
particles, as evidenced by increased small HDL particles (P<0.05) and reduced paraoxonase-
1 activities. Significant increase in both pro-oxidant-antioxidant balance and ischemia-
modified albumin (P<0.05), with simultaneously decreased activity of superoxide-dismutase
(P<0.05) was found in patients with progressive diabetic neuropathy, indicating the highest
degree of oxidative damage. It can be concluded that patients with microvascular
complications of DM have aggravated redox imbalance and lipid profile alterations. In
addition to metabolic control, strategies aimed at lowering OS and correcting dyslipidemia
can contribute to the prevention of microvascular complications of diabetes., Neenzimska glikacija, oksidativni stres (OS) i dislipidemija su glavni metabolički
procesi koji dovode do razvoja makrovaskularnih komplikacija (kardiovaskularnih bolesti)
dijabetesa melitusa (DM). Međutim, klinički značaj određivanja biomarkera ovih procesa
kod pacijenata sa mikrovaskularnim komplikacijama (retinopatija, nefropatija, neuropatija)
nije dovoljno razjašnjen. Cilj ovog istraživanja je bio ispitivanje produkata uznapredovale
glikacije (AGE), biomarkera OS i dislipidemije kod 100 pacijenata sa DM (33 bez
mikrovaskularnih komplikacija i 77 sa komplikacijama) i 30 ispitanika bez DM. Nivo
cirkulišućih AGE je bio značajno viši u grupi pacijenata sa komplikacijama (medijana: 5,72;
interkvartilni raspon: 4,60-6,54 U/mL) u odnosu na pacijente bez komplikacija (medijana:
4,84; interkvartilni raspon 4,10-5,40 U/L; P<0,05). Pored povišenih koncentracija AGE,
pacijenti sa dijabetesnom retinopatijom su imali i povišene vrednosti totalnog oksidativnog
statusa (P<0,05), a pacijenti sa dijabetesnom nefropatijom manje dijametre LDL čestica
(25,48±1,26 nm) u poređenju sa sa pacijentima bez komplikacija (26,21±1,19 nm;
P<0,05). Nadalje, kod pacijenata sa pridruženim makrovaskularnim komplikacijama
(kardiovaskularnim bolestima) utvrđeno je prisustvo disfunkcionalnih HDL čestica, na
osnovu povećanog udela malih HDL čestica (P<0.05) i smanjene aktivnosti paroksonaze-
1. Pacijenti sa progresivnom dijabetesnom neuropatijom su imali značajno povišene
vrednosti prooksidativno-antioksidativnog balansa i ishemijom modifikovanog albumina
(P<0,05), uz istovremeno sniženje aktivnosti superoksid-dismutaze (P<0,05), što ukazuje da
je stepen oksidativnog oštećenja u ovoj grupi bio najveći. Može se zaključiti da, pored
adekvatne metaboliče kontrole, strategije usmerene ka sniženju OS i korekciji dislipidemije,
mogu doprineti prevenciji razvoja mikrovaskularnih komplikacija dijabetesa.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "The importance of advanced glycation end products, lipid and redox biomarkers determination in patients with diabetes mellitus, Značaj određivanja produkata uznapredovale glikacije i biomarkera lipidnog i redoks statusa kod pacijenata sa dijabetes melitusom",
volume = "72",
number = "4 suplement",
pages = "S229-S230",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4509"
}

Vujčić, S., Kotur-Stevuljević, J., Beljić Živković, T., Mišić, M., Mihajlović, M., Erceg, S., Zeljković, A., Koprivica‐Uzelac, B., Perović‐Blagojević, I.,& Vekić, J.. (2022). The importance of advanced glycation end products, lipid and redox biomarkers determination in patients with diabetes mellitus. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S229-S230.
https://hdl.handle.net/21.15107/rcub_farfar_4509

Vujčić S, Kotur-Stevuljević J, Beljić Živković T, Mišić M, Mihajlović M, Erceg S, Zeljković A, Koprivica‐Uzelac B, Perović‐Blagojević I, Vekić J. The importance of advanced glycation end products, lipid and redox biomarkers determination in patients with diabetes mellitus. in Arhiv za farmaciju. 2022;72(4 suplement):S229-S230.
https://hdl.handle.net/21.15107/rcub_farfar_4509 .

Vujčić, Sanja, Kotur-Stevuljević, Jelena, Beljić Živković, Teodora, Mišić, Milan, Mihajlović, Marija, Erceg, Sanja, Zeljković, Aleksandra, Koprivica‐Uzelac, Branka, Perović‐Blagojević, Iva, Vekić, Jelena, "The importance of advanced glycation end products, lipid and redox biomarkers determination in patients with diabetes mellitus" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S229-S230,
https://hdl.handle.net/21.15107/rcub_farfar_4509 .

TY  - JOUR
AU  - Petković, Aleksa
AU  - Erceg, Sanja
AU  - Munjas, Jelena
AU  - Ninić, Ana
AU  - Sopić, Miron
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4186
AB  - Coronary artery disease (CAD) is a leading cause of mortality worldwide. Atherosclerosis
involves an interplay of different pathological mechanisms, such as progressive inflammation,
abnormal lipid metabolism, and oxidative stress, and as such represents the basic pathological
phenomenon underlying CAD. Atherosclerotic plaque narrows the lumen of coronary arteries,
creating an ischemic environment for the heart muscle, which finally leads to clinical
complications, such as acute myocardial infarction. Currently, there are no biomarkers that could
predict plaque stability or major adverse cardiovascular events (MACE). Numerous functional
non-coding RNA (ncRNA) species influence basic cellular functions, and as such play a role in
the development and progression of CAD. Of these ncRNAs, micro RNAs (miRNAs) and long
non-coding RNAs (lncRNAs) are the most investigated. Considering that ncRNAs detected in
extracellular fluids can originate from different cells, circulating ncRNAs are being intensively
investigated as potential biomarkers in the diagnosis and prognosis of CAD. In the following
paper, we provide current insights into potential molecular mechanisms by which miRNAs and
lncRNAs contribute to the pathology of CAD and discuss their potential role as biomarkers in
diagnosis and prognosis of disease.
AB  - Koronarna arterijska bolest (KAB) predstavlja vodeći uzrok smrtnosti širom sveta. Osnovni patološki proces koji karakteriše KAB je ateroskleroza, koju odlikuju različiti patofiziološki mehanizmi kao što su progresivna inflamacija, poremećen metabolizam lipida, oksidativni stres, itd. Aterosklerotski plak sužava lumen koronarnih arterija, što dovodi do nastanka ishemijskih promena na srčanom mišiću, posledično dovodeći do kliničkih komplikacija ove bolesti, kao što je akutni infarkt miokarda. Trenutno ne postoje biomarkeri koji bi mogli da predvide sudbinu aterosklerotskog plaka, kao ni razvoj akutnih koronarnih događaja ili razvoj velikih uznapredovalih kardiovaskularnih događaja. Mnogobrojne vrste nekodirajućih RNK molekula utiču na osnovne ćelijske funkcije i kao takve igraju ulogu u nastanku i progresiji KAB. Do sada su od svih vrsta nekodirajućih RNK-a najviše istražene mikro RNK-a (miRNK) i dugolančane nekodirajuće RNK-a (dnkRNK). Uzimajući u obzir da nekodirajuće RNK-a dospevaju u ekstracelularnu tečnost iz različitih ćelija, trenutno se veliki napori ulažu u ispitivanje mogućnosti upotrebe cirkulišuih nekodirajućih RNK-a kao potencijalnih biomarkera u dijagnostici i prognostici KAB. U ovom naučno-istraživačkom članku sažećemo trenutna saznanja o molekularnim mehanizmima preko kojih miRNK i dnkRNK doprinose razvoju KAB, kao i o potencijalnoj primeni ovih molekula kao budućih biomarkera u dijagnozi i prognozi ove bolesti.
PB  - Beograd : Savez farmaceutskih udruženja Srbije
T2  - Arhiv za farmaciju
T1  - Circulating non-coding RNAs as biomarkers in coronary artery disease
T1  - Cirkulišuće nekodirajuće RNK kao biomarkeri u koronarnoj arterijskoj bolesti
VL  - 72
IS  - 2
SP  - 149
EP  - 165
DO  - 10.5937/arhfarm72-36166
ER  - 

@article{
author = "Petković, Aleksa and Erceg, Sanja and Munjas, Jelena and Ninić, Ana and Sopić, Miron",
year = "2022",
abstract = "Coronary artery disease (CAD) is a leading cause of mortality worldwide. Atherosclerosis
involves an interplay of different pathological mechanisms, such as progressive inflammation,
abnormal lipid metabolism, and oxidative stress, and as such represents the basic pathological
phenomenon underlying CAD. Atherosclerotic plaque narrows the lumen of coronary arteries,
creating an ischemic environment for the heart muscle, which finally leads to clinical
complications, such as acute myocardial infarction. Currently, there are no biomarkers that could
predict plaque stability or major adverse cardiovascular events (MACE). Numerous functional
non-coding RNA (ncRNA) species influence basic cellular functions, and as such play a role in
the development and progression of CAD. Of these ncRNAs, micro RNAs (miRNAs) and long
non-coding RNAs (lncRNAs) are the most investigated. Considering that ncRNAs detected in
extracellular fluids can originate from different cells, circulating ncRNAs are being intensively
investigated as potential biomarkers in the diagnosis and prognosis of CAD. In the following
paper, we provide current insights into potential molecular mechanisms by which miRNAs and
lncRNAs contribute to the pathology of CAD and discuss their potential role as biomarkers in
diagnosis and prognosis of disease., Koronarna arterijska bolest (KAB) predstavlja vodeći uzrok smrtnosti širom sveta. Osnovni patološki proces koji karakteriše KAB je ateroskleroza, koju odlikuju različiti patofiziološki mehanizmi kao što su progresivna inflamacija, poremećen metabolizam lipida, oksidativni stres, itd. Aterosklerotski plak sužava lumen koronarnih arterija, što dovodi do nastanka ishemijskih promena na srčanom mišiću, posledično dovodeći do kliničkih komplikacija ove bolesti, kao što je akutni infarkt miokarda. Trenutno ne postoje biomarkeri koji bi mogli da predvide sudbinu aterosklerotskog plaka, kao ni razvoj akutnih koronarnih događaja ili razvoj velikih uznapredovalih kardiovaskularnih događaja. Mnogobrojne vrste nekodirajućih RNK molekula utiču na osnovne ćelijske funkcije i kao takve igraju ulogu u nastanku i progresiji KAB. Do sada su od svih vrsta nekodirajućih RNK-a najviše istražene mikro RNK-a (miRNK) i dugolančane nekodirajuće RNK-a (dnkRNK). Uzimajući u obzir da nekodirajuće RNK-a dospevaju u ekstracelularnu tečnost iz različitih ćelija, trenutno se veliki napori ulažu u ispitivanje mogućnosti upotrebe cirkulišuih nekodirajućih RNK-a kao potencijalnih biomarkera u dijagnostici i prognostici KAB. U ovom naučno-istraživačkom članku sažećemo trenutna saznanja o molekularnim mehanizmima preko kojih miRNK i dnkRNK doprinose razvoju KAB, kao i o potencijalnoj primeni ovih molekula kao budućih biomarkera u dijagnozi i prognozi ove bolesti.",
publisher = "Beograd : Savez farmaceutskih udruženja Srbije",
journal = "Arhiv za farmaciju",
title = "Circulating non-coding RNAs as biomarkers in coronary artery disease, Cirkulišuće nekodirajuće RNK kao biomarkeri u koronarnoj arterijskoj bolesti",
volume = "72",
number = "2",
pages = "149-165",
doi = "10.5937/arhfarm72-36166"
}

Petković, A., Erceg, S., Munjas, J., Ninić, A.,& Sopić, M.. (2022). Circulating non-coding RNAs as biomarkers in coronary artery disease. in Arhiv za farmaciju
Beograd : Savez farmaceutskih udruženja Srbije., 72(2), 149-165.
https://doi.org/10.5937/arhfarm72-36166

Petković A, Erceg S, Munjas J, Ninić A, Sopić M. Circulating non-coding RNAs as biomarkers in coronary artery disease. in Arhiv za farmaciju. 2022;72(2):149-165.
doi:10.5937/arhfarm72-36166 .

Petković, Aleksa, Erceg, Sanja, Munjas, Jelena, Ninić, Ana, Sopić, Miron, "Circulating non-coding RNAs as biomarkers in coronary artery disease" in Arhiv za farmaciju, 72, no. 2 (2022):149-165,
https://doi.org/10.5937/arhfarm72-36166 . .